The Global Health Body Issues Alert Over Severe Scarcity of Obesity Injections
Fewer than 10% of patients that would benefit from GLP-1 drugs including Wegovy have access to them, warns the global health agency as it publishes its inaugural guidance on the drugs.
With more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be managed with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to widespread availability to the treatments that can help people shift substantial weight, notes the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic case, the production of such drugs could only cover about 100 million people – under 10% of those who need them, per the health organization.
The advice encourages countries and companies to expand availability, via strategies like voluntary licensing.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Work
The injections mimick a natural hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
Patients usually start to lose weight after several weeks of commencing the once-weekly jabs.
Research suggests users may put most of the weight back on after a year of discontinuing the medication, because their usual hunger resume.
Being above a healthy weight elevates your risk for developing diseases, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
